Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Clinical trial NCT02100930 · COMPLETED
Trial details
- NCT number
- NCT02100930
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-01
- Primary completion
- 2019-03-07
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.